Table 3.
The predictor for nonresponse to bevacizumab combination therapy applied to the training cohort.
Training cohort | Predictor for nonresponse | |
---|---|---|
Negative test for nonresponse Methylated (≥ 12%) |
Positive test for nonresponse Nonmethylated (< 12%) |
|
Nonresponse | 32 (56%) | 19 (95%) |
Response | 25 (44%) | 1 (5%) |
Total | 57 | 20 |